The estimated Net Worth of David Lawrence is at least $4.74 Milione dollars as of 2 December 2019. Mr. Lawrence owns over 1,176 units of Acorda Therapeutics Inc stock worth over $8,554 and over the last 19 years he sold ACOR stock worth over $3,821,525. In addition, he makes $912,816 as Chief Business Operations e Principal Accounting Officer at Acorda Therapeutics Inc.
David has made over 56 trades of the Acorda Therapeutics Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently he sold 1,176 units of ACOR stock worth $1,882 on 2 December 2019.
The largest trade he's ever made was exercising 63,183 units of Acorda Therapeutics Inc stock on 9 February 2017 worth over $1,398,240. On average, David trades about 5,317 units every 60 days since 2006. As of 2 December 2019 he still owns at least 12,961 units of Acorda Therapeutics Inc stock.
You can see the complete history of Mr. Lawrence stock trades at the bottom of the page.
David Lawrence serves as Chief Business Operations, Principal Accounting Officer of Acorda Therapeutics, Inc. He has been our Chief, Business Operations and Principal Accounting Officer since October 2016. Prior to that, he served as Chief of Business Operations from October 2013 to October 2016. From January 2005 to October 2013, he served as our Chief Financial Officer. He previously served as our Vice President, Finance from January 2001 through 2004, and Director, Finance from 1999 to 2001. From 1991 to 1999, Mr. Lawrence held several positions for Tel-Air Communications, Inc., including Vice President and Controller. Prior to Tel-Air, he held the financial management positions of Controller and Finance Manager for Southwestern Bell and Metromedia Telecommunications, respectively. Mr. Lawrence received his undergraduate degree in Accounting from Roger Williams College, and an M.B.A. in Finance from Iona College. Mr. Lawrence is a founding member and currently serves on the board of directors and as Treasurer of The Brian Ahearn Children’s Fund.
As the Chief Business Operations e Principal Accounting Officer of Acorda Therapeutics Inc, the total compensation of David Lawrence at Acorda Therapeutics Inc is $912,816. There are 4 executives at Acorda Therapeutics Inc getting paid more, with Ron Cohen having the highest compensation of $2,039,560.
David Lawrence is 62, he's been the Chief Business Operations e Principal Accounting Officer of Acorda Therapeutics Inc since 2016. There are 11 older and 6 younger executives at Acorda Therapeutics Inc. The oldest executive at Acorda Therapeutics Inc is Lorin Randall, 76, who is the Independent Director.
Over the last 19 years, insiders at Acorda Therapeutics Inc have traded over $155,173,492 worth of Acorda Therapeutics Inc stock and bought 1,139,691 units worth $17,085,546 . The most active insiders traders include Capital Management Lp Scopi..., Ian F Smith e Ron Cohen. On average, Acorda Therapeutics Inc executives and independent directors trade stock every 19 days with the average trade being worth of $19,752. The most recent stock trade was executed by Ron Cohen on 16 March 2023, trading 20,156 units of ACOR stock currently worth $12,497.
acorda therapeutics is a publicly traded (nasdaq: acor) biotechnology company whose mission is to develop therapies that restore neurological function and improve the lives of people with neurological disorders. we started our company in 1995 as a network of scientists, physicians and business people with a common belief that sharing ideas and information could lead to innovative medical advances for people with neurological disorders. we have since evolved into a commercial-stage biotechnology company, successfully developing and commercializing important therapies that advance the care of people affected by neurological conditions. we achieve our goals by: • investing in research and development • collaborating closely with the patient, medical and scientific communities • retaining employees with compassion and commitment acorda has been voted one of the best companies to work for in new york for the past five years in a row, as a result of our dynamic environment, strong corporate
Acorda Therapeutics Inc executives and other stock owners filed with the SEC include: